ctp-518

CTP-518 is a **novel HIV protease inhibitor** developed using deuterium chemistry by Concert Pharmaceuticals. It is a stable isotopolog of atazanavir in which certain hydrogen atoms are replaced with **deuterium**. This modification fully retains the antiviral potency of atazanavir but markedly slows down hepatic metabolism, resulting in improved half-life and higher plasma trough levels. The primary clinical goal of CTP-518 was to enable once-daily oral administration without the need for a pharmacokinetic boosting agent such as ritonavir, eliminating related side effects and drug interactions. CTP-518 reached Phase 1 clinical trials for the treatment of HIV infection but development has been discontinued[1][3][4][5][7][9].

Other names

deuterium-modified atazanavir